Posted: 11 November 2025
Clinical-stage biotechnology company Noxopharm Limited has been awarded a $25,000 NSW Government TechVoucher grant to support a joint research project with UNSW Sydney exploring the potential of its Sofra™ technology platform.
The TechVouchers program supports partnerships between small to medium enterprises and research organisations to advance new products and services. This early-stage feasibility study will investigate how Noxopharm’s novel anti-inflammatory oligonucleotides from the Sofra™ platform could help reduce inflammation caused by medical implants.
Matched funding will be provided by Noxopharm to progress the collaborative initiative.
Noxopharm CEO Dr Gisela Mautner said the funding highlighted the versatility of the company’s proprietary platform.
“This grant is another illustration of the potential of our technology which, because of its ability to mitigate inflammation, could one day be used in a wide variety of settings,” Dr Mautner said. “UNSW has been a longstanding collaborator, and we are very much looking forward to benefiting from their expertise and insights as this study progresses.”
Developed from a breakthrough discovery in the immune system, Sofra™ is a novel drug platform targeting inflammatory and autoimmune diseases, RNA therapeutics and vaccines. Its oligonucleotide-based compounds regulate inflammation at its source and have potential applications across conditions such as rheumatoid arthritis, lupus, diabetes, and cancer.
The global autoimmune disease therapeutics market was valued at US$163.2 billion in 2024 and is forecast to reach US$219.6 billion by 2035, underscoring the significance of innovations in this field.
Noxopharm continues to build a pipeline of new proprietary drugs through its Sofra™ and Chroma™ technology platforms in collaboration with leading research partners.
